Defining the needle in a haystack: A compendium of genomic, pathologic, and clinical characteristics of rare pulmonary tumors.

Autor: Shields MD; Department of Internal Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine (IUSOM), Indianapolis, IN 46202, USA., Minton KG; Department of Internal Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine (IUSOM), Indianapolis, IN 46202, USA., Tran M; Department of Pharmacology and Toxicology, IUSOM., Gunderman PR; Department of Radiology, IUSOM., Larsson LG; Department of Pathology, IUSOM., Guo S; Department of Pathology, IUSOM., Kniese CM; Department of Pulmonary Medicine, IUSOM., Wei CX; Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA., Marin-Acevedo JA; Department of Internal Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine (IUSOM), Indianapolis, IN 46202, USA., Maniar R; Department of Internal Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine (IUSOM), Indianapolis, IN 46202, USA., Durm GA; Department of Internal Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine (IUSOM), Indianapolis, IN 46202, USA., He W; Department of Internal Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine (IUSOM), Indianapolis, IN 46202, USA., Hanna NH; Department of Internal Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine (IUSOM), Indianapolis, IN 46202, USA. Electronic address: nhanna@iu.edu.
Jazyk: angličtina
Zdroj: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Dec 27; Vol. 199, pp. 108035. Date of Electronic Publication: 2024 Dec 27.
DOI: 10.1016/j.lungcan.2024.108035
Abstrakt: A major paradigm shift in the diagnosis, management, and survival outcomes of early and advanced non-small cell lung cancer has transpired over the past few decades in thoracic oncology with the incorporation of molecular testing, targeted therapy, immunotherapy, neoadjuvant, and adjuvant approaches. However, transformation in the management and survival outcomes of rare lung tumors is lacking. Given the scarcity of these tumor types, randomized trials are rarely performed, and treatment is extrapolated from case series, tumor-agnostic trials, or cancers with similar histology. Literature informing the management of rare pulmonary tumors is typically limited to a single histology, unique features, or extraordinary responses to therapy. Few resources detailing genomic characteristics and delineating features of these tumors are available, often resulting in suboptimal treatment. Here, we explore the clinical, histopathologic, genomic features and potential therapies of five rare pulmonary tumors, namely adenosquamous, basaloid squamous, mucoepidermoid, carcinosarcoma, and NUT carcinoma, to build a resource for rare histological subtypes of the lung and emphasize knowledge gaps in the management of these tumors. Our recommendations are based on a comprehensive review of case reports and series, clinical trials, and the "Indiana University Experience."
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Misty D. Shields: Received payment for speakers bureau from Jazz Pharmaceuticals, participation in advisory board for AstraZeneca and Jazz Pharmaceuticals. These relationships have ended. Katherine G. Minton: No disclosures. Peter R. Gunderman: No disclosures. Lisabeth G. Larsson: No disclosures. Shunhua Guo: No disclosures. Christopher M. Kniese: Received payment for consulting services from Cook Medical. Cynthia X. Wei: No disclosures. Julian A. Marin-Acevedo: No disclosures. Rohan Maniar: Intellectual property contributor for patent including, “TCF1 as a blood biomarker of immunotherapy response.” Greg A. Durm: Received manuscript support from Bristol Myers Squibb (payment to institution), received institutional support with grant funding for research (payment to institution) from AstraZeneca, Merck, and Mirati. Received payments for consulting services from Cook Biotech, and received payments for honoraria/presentations with Curio Sciences, DAVA Oncology, and AstraZeneca. Participated in advisory board for Curio Sciences, DAVA Oncology, and AstraZeneca. Weston He: No disclosures. Mya Tran: No disclosures. Nasser H. Hanna: Institution received grant funding for research (payment to institution) from AstraZeneca, Merck, Genentech, and Natera.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: